Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comment
. 2021 Oct;26(10):e1895-e1896.
doi: 10.1002/onco.13886. Epub 2021 Jul 17.

In Reply

Francesca Salani  1 , Clara Ugolini  2 , Silvia Catanese  1 , Andrea Cacciato Insilla  2 , Lorenzo Fornaro  1 , Daniela Campani  2 , Enrico Vasile  1 , Gabriella Fontanini  2 , Gianluca Masi  1   3 , Caterina Vivaldi  1   3
Affiliations
Comment

In Reply

Francesca Salani et al. Oncologist. 2021 Oct.

Abstract

This letter to the editor responds to comments by Hori et al. on the recently published study on intrahepatic cholangiocarcinoma and HER2 positivity rate.

PubMed Disclaimer

Comment on

References

    1. Hori Y, Yoh T, Seo S et al. Limited impact of HER2 expression on survival outcomes in patients with intrahepatic cholangiocarcinoma after surgical resection. The Oncologist 2021;26:XXXX–XXXX. - PMC - PubMed
    1. Valle JW, Borbath I, Khan SA et al. Biliary cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow‐up. Ann Oncol 2016;27(suppl 5):v28–v37. - PubMed
    1. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines): Hepatobiliary Cancers. Version 5.2020. Plymouth Meeting, PA: National Comprehensive Cancer Network, 2020.
    1. Galdy S, Lamarca A, McNamara MG, et al. HER2/HER3 pathway in biliary tract malignancies; systematic review and meta‐analysis: A potential therapeutic target? Cancer Metastasis Rev 2017;36:141–157. - PMC - PubMed
    1. Weinberg BA, Xiu J, Lindberg MR et al. Molecular profiling of biliary cancers reveals distinct molecular alterations and potential therapeutic targets. J Gastrointest Oncol 2019;10:652–662. - PMC - PubMed